News Quantified

URGN – urogen pharma ltd. - ordinary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Urogen Pharma (URGN) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $40.00 price target on the stock.

UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer

Why The UroGen Pharma (URGN) Investment Story Is Shifting As Analysts Hold Fair Value Steady [Yahoo! Finance]

Urogen Pharma (URGN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $33.00 price target on the stock.

Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI

-13.2%

BEAT

30.0%

BEAT

-7.6%

MISS

12.5%

MISS

Oppenheimer Holdings, Inc.

Form PRE 14A UroGen Pharma Ltd. For: Dec 31

Form 10-K UroGen Pharma Ltd. For: Dec 31

Form 8-K UroGen Pharma Ltd. For: Mar 02

Form 8-K UroGen Pharma Ltd. For: Feb 26

Form 4 UroGen Pharma Ltd. For: Feb 26 Filed by: Robinson James A. Jr.

Top News Gainers

3/23 Form 8-K UroGen Pharma Ltd. For: Mar 20 18.6%

11/12 Q3/2019 9/30/2019 EPS -1.060 ZacksConsensus -1.260 ActVsEst 0.200 - Beat 13.6%

4/13 Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. 11.3%

4/17 Urogen Pharma Ltd (NASDAQ: URGN) had its price target raised by analysts at Oppenheimer Holdings Inc. from $45.00 to $47.00. They now have an "outperform" rating on the stock. 9.9%

4/16 UruGen shares jump 10% on FDA approval of rare cancer treatment [MarketWatch] 9.6%

4/3 UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer 8.1%

11/18 Form 4 UroGen Pharma Ltd. For: Nov 14 Filed by: Mullennix Stephen 8.0%

12/6 UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 6.7%

2/14 Form SC 13G/A UroGen Pharma Ltd. Filed by: Wildcat Capital Management, LLC 6.6%

1/16 Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at Cowen Inc. 6.5%

Top News Decliners

9/24 Form 8-K UroGen Pharma Ltd. For: Sep 24 -19.9%

4/30 The Lancet Oncology Publishes Details of UroGen Pharma’s Pivotal OLYMPUS Trial -12.2%

4/16 Form 8-K UroGen Pharma Ltd. For: Apr 15 -7.8%

2/12 Form SC 13D/A UroGen Pharma Ltd. Filed by: Arkin Moshe -5.3%

11/12 UroGen Pharma Ltd. (URGN) Q3 2019 Earnings Call Transcript [The Motley Fool] -4.9%

8/5 UroGen Pharma to Report Second Quarter 2019 Financial Results on Friday, August 9, 2019 -4.7%

5/11 UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -4.6%

5/28 Form 8-K UroGen Pharma Ltd. For: May 21 -4.5%

9/26 Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at Cowen Inc. -4.4%

5/9 UroGen Pharma Ltd. (URGN) Q1 2019 Earnings Call Transcript [The Motley Fool] -3.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day